EA202090640A1 - Получение твердых лекарственных форм, содержащих антитела, путем наслаивания раствора/суспензии - Google Patents
Получение твердых лекарственных форм, содержащих антитела, путем наслаивания раствора/суспензииInfo
- Publication number
- EA202090640A1 EA202090640A1 EA202090640A EA202090640A EA202090640A1 EA 202090640 A1 EA202090640 A1 EA 202090640A1 EA 202090640 A EA202090640 A EA 202090640A EA 202090640 A EA202090640 A EA 202090640A EA 202090640 A1 EA202090640 A1 EA 202090640A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- suspension
- solution
- containing antibodies
- laying
- forms containing
- Prior art date
Links
- 239000000725 suspension Substances 0.000 title abstract 2
- 239000007787 solid Substances 0.000 title 1
- 239000007909 solid dosage form Substances 0.000 abstract 3
- 238000013268 sustained release Methods 0.000 abstract 2
- 239000012730 sustained-release form Substances 0.000 abstract 2
- 239000011248 coating agent Substances 0.000 abstract 1
- 238000000576 coating method Methods 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 210000001035 gastrointestinal tract Anatomy 0.000 abstract 1
- 239000012729 immediate-release (IR) formulation Substances 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000000699 topical effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
- A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Endocrinology (AREA)
- Inorganic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Изобретение относится к способу получения твердых лекарственных форм для немедленного и продолжительного высвобождения, содержащих антитела и их функциональные фрагменты, путем наслаивания раствора/суспензии, необязательно покрытые покрытием для замедленного высвобождения; твердым лекарственным формам, полученным с применением указанного способа; и применению твердых лекарственных форм при местном лечении в желудочно-кишечном тракте пациента.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP17192260.2A EP3459528B1 (en) | 2017-09-20 | 2017-09-20 | Preparation of solid dosage forms comprising antibodies by solution/suspension layering |
PCT/EP2018/074520 WO2019057562A1 (en) | 2017-09-20 | 2018-09-11 | PREPARATION OF SOLID GALENIC SHAPES COMPRISING ANTIBODIES BY SOLUTION / SUSPENSION STRATIFICATION |
Publications (2)
Publication Number | Publication Date |
---|---|
EA202090640A1 true EA202090640A1 (ru) | 2020-06-15 |
EA202090640A8 EA202090640A8 (ru) | 2021-12-28 |
Family
ID=59923358
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA202090640A EA202090640A8 (ru) | 2017-09-20 | 2018-09-11 | Получение твердых лекарственных форм, содержащих антитела, путем наслаивания раствора/суспензии |
Country Status (23)
Country | Link |
---|---|
US (2) | US11826470B2 (ru) |
EP (2) | EP3459528B1 (ru) |
JP (2) | JP7204743B2 (ru) |
KR (1) | KR20200055711A (ru) |
CN (1) | CN111093635A (ru) |
AR (1) | AR112901A1 (ru) |
AU (1) | AU2018337493A1 (ru) |
BR (1) | BR112020005460A8 (ru) |
CA (1) | CA3075862A1 (ru) |
CL (1) | CL2020000735A1 (ru) |
CO (1) | CO2020003070A2 (ru) |
CR (2) | CR20200130A (ru) |
EA (1) | EA202090640A8 (ru) |
ES (1) | ES2938609T3 (ru) |
GE (2) | GEP20227351B (ru) |
IL (1) | IL272933A (ru) |
JO (1) | JOP20200064A1 (ru) |
MA (1) | MA50157A (ru) |
MX (1) | MX2020003032A (ru) |
PH (1) | PH12020500353A1 (ru) |
SG (1) | SG11202002203YA (ru) |
TW (1) | TWI802592B (ru) |
WO (1) | WO2019057562A1 (ru) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112263564B (zh) * | 2020-10-30 | 2022-07-19 | 黄山中皇制药有限公司 | 一种喜炎平干混悬剂的制备方法 |
CN112107694B (zh) * | 2020-10-30 | 2022-07-22 | 黄山中皇制药有限公司 | 一种喜炎平干混悬剂 |
Family Cites Families (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
IT1241417B (it) | 1990-03-06 | 1994-01-14 | Vectorpharma Int | Composizioni terapeutiche a rilascio controllato di farmaci supportatisu polimeri reticolati e rivestiti con film polimerici,e loro processodi preparazione |
IT1246382B (it) | 1990-04-17 | 1994-11-18 | Eurand Int | Metodo per la cessione mirata e controllata di farmaci nell'intestino e particolarmente nel colon |
GB9109645D0 (en) | 1991-05-03 | 1991-06-26 | Celltech Ltd | Recombinant antibodies |
US5919452A (en) | 1991-03-18 | 1999-07-06 | New York University | Methods of treating TNFα-mediated disease using chimeric anti-TNF antibodies |
CA2110899C (en) | 1991-06-21 | 2006-08-08 | Jacob G. Michael | Orally administrable therapeutic proteins and method of making |
JPH09503754A (ja) | 1993-09-20 | 1997-04-15 | アナデイス・リミテツド | 初乳から免疫グロブリンを得る方法および医薬組成物におけるそれらの使用 |
NO309690B1 (no) | 1995-01-23 | 2001-03-12 | Western Atlas Int Inc | Detonasjonsanordning av type eksploderende brotråd for bruk med et perforeringsverktöy i en brönn |
WO2000018500A1 (de) | 1998-09-24 | 2000-04-06 | Glatt Systemtechnik Dresden Gmbh | Einrichtung zur herstellung eines schüttfähigen produktes und verfahren zur anwendung der einrichtung |
ATE341619T1 (de) | 1997-12-20 | 2006-10-15 | Genencor Int | In einem wirbelschichtbett hergestelltes matrixgranulat |
US6074689A (en) | 1998-03-10 | 2000-06-13 | Immucell Corporation | Colonic delivery of protein or peptide compositions |
FI20000780A (fi) | 2000-04-03 | 2001-10-04 | Novasso Oy | Peroraalinen lääkemuoto lääkeaineen hallituksi vapauttamiseksi |
GB2367002A (en) | 2000-09-25 | 2002-03-27 | British Sugar Plc | Coating composition |
GB0203421D0 (en) | 2002-02-13 | 2002-04-03 | Alizyme Therapeutics Ltd | Composition |
US9107804B2 (en) | 2002-12-10 | 2015-08-18 | Nortec Development Associates, Inc. | Method of preparing biologically active formulations |
ES2645930T3 (es) | 2003-01-03 | 2017-12-11 | Supernus Pharmaceuticals, Inc. | Utilización de una mezcla de dos o más materiales entéricos para regular la liberación de fármacos a través de una membrana o matriz para terapias sistémicas |
DE10332160A1 (de) | 2003-07-15 | 2005-02-03 | Röhm GmbH & Co. KG | Multipartikuläre Arzneiform, enthaltend mucoadhaesiv formulierte Peptid- oder Protein-Wirkstoffe, sowie ein Verfahren zur Herstellung der Arzneiform |
DE10353196A1 (de) | 2003-11-13 | 2005-06-16 | Röhm GmbH & Co. KG | Mehrschichtige Arzneiform mit einer die Abgabe einer modulatorischen Substanz beeinflussenden Matrix |
DE10353186A1 (de) | 2003-11-13 | 2005-06-16 | Röhm GmbH & Co. KG | Mehrschichtige Arzneiform, enthaltend eine in Bezug auf die Wirkstoffabgabe modulatorisch wirkende Substanz |
CA2566311A1 (en) | 2004-05-19 | 2005-12-08 | Glatt Air Techniques, Inc. | Micropellet containing pellets and method of preparing such pellets |
BRPI0609598A2 (pt) | 2005-03-29 | 2010-04-20 | Roehm Gmbh | forma farmacêutica multiparticulada compreendendo péletes com uma substáncia possuindo um efeito modular em relação à liberação de ingrediente ativo |
BRPI0611765B1 (pt) | 2005-06-07 | 2022-09-27 | Esbatech Ag | Anticorpo ou fragmento de anticorpo estável e solúvel que se liga especificamente ao tnf-alfa seus usos e composição diagnóstica ou terapêutica |
CN103301070A (zh) | 2006-02-09 | 2013-09-18 | 阿尔巴医疗公司 | 紧密连接效应子的制剂 |
GB0607534D0 (en) | 2006-04-13 | 2006-05-24 | Univ London Pharmacy | Colonic drug delivery formulation |
WO2008117814A1 (ja) * | 2007-03-26 | 2008-10-02 | Teikoku Seiyaku Co., Ltd. | 大腸送達用経口製剤 |
US20100239682A1 (en) * | 2007-09-17 | 2010-09-23 | Antoine Andremont | Colonic delivery of antimicrobial agents |
CA2615137A1 (en) * | 2007-12-17 | 2009-06-17 | Pharmascience Inc. | Single layered controlled release therapeutic system |
US20110008423A1 (en) | 2008-01-03 | 2011-01-13 | Abbott Products Gmbh | Pharmaceutical compositions comprising granules of purified microbial lipase and methods for preventing or treating digestive disorders |
PT3444274T (pt) | 2008-06-25 | 2021-03-17 | Novartis Ag | Anticorpos que inibem tnf estáveis e solúveis |
ES2677003T3 (es) | 2008-06-25 | 2018-07-27 | Esbatech, An Alcon Biomedical Research Unit Llc | Humanización de anticuerpos de conejo utilizando un marco universal de anticuerpos |
KR20110031373A (ko) | 2008-07-10 | 2011-03-25 | 에스바테크, 언 알콘 바이오메디칼 리서치 유닛 엘엘씨 | 마크로분자 전달을 증강하는 방법 및 조성물 |
EP2340812A1 (en) | 2009-12-18 | 2011-07-06 | Ferring International Center S.A. | Granules for pharmaceutical preparations, methods and apparatus for their production |
ES2688591T3 (es) * | 2011-03-28 | 2018-11-05 | Ablynx N.V. | Método para producir formulaciones sólidas que comprenden dominios variables individuales de inmunoglobulina |
WO2014142938A1 (en) | 2013-03-15 | 2014-09-18 | Aihol Corporation | Pharmaceutical formulation containing glycosaminoglycan |
FR3022462B1 (fr) * | 2014-06-18 | 2018-04-27 | Laboratoire Francais Du Fractionnement Et Des Biotechnologies | Composition orale d'anticorps anti-tnfalpha |
-
2017
- 2017-09-20 EP EP17192260.2A patent/EP3459528B1/en active Active
- 2017-09-20 ES ES17192260T patent/ES2938609T3/es active Active
-
2018
- 2018-09-11 JO JOP/2020/0064A patent/JOP20200064A1/ar unknown
- 2018-09-11 AU AU2018337493A patent/AU2018337493A1/en active Pending
- 2018-09-11 CN CN201880059373.2A patent/CN111093635A/zh active Pending
- 2018-09-11 KR KR1020207006918A patent/KR20200055711A/ko not_active Application Discontinuation
- 2018-09-11 BR BR112020005460A patent/BR112020005460A8/pt unknown
- 2018-09-11 CR CR20200130A patent/CR20200130A/es unknown
- 2018-09-11 MX MX2020003032A patent/MX2020003032A/es unknown
- 2018-09-11 JP JP2020515749A patent/JP7204743B2/ja active Active
- 2018-09-11 EP EP18765136.9A patent/EP3684339A1/en active Pending
- 2018-09-11 GE GEAP201815318A patent/GEP20227351B/en unknown
- 2018-09-11 EA EA202090640A patent/EA202090640A8/ru unknown
- 2018-09-11 SG SG11202002203YA patent/SG11202002203YA/en unknown
- 2018-09-11 CA CA3075862A patent/CA3075862A1/en active Pending
- 2018-09-11 WO PCT/EP2018/074520 patent/WO2019057562A1/en active Application Filing
- 2018-09-11 MA MA050157A patent/MA50157A/fr unknown
- 2018-09-11 CR CR20210203A patent/CR20210203A/es unknown
- 2018-09-11 GE GEAP201815611A patent/GEP20237504B/en unknown
- 2018-09-11 US US16/647,322 patent/US11826470B2/en active Active
- 2018-09-17 TW TW107132680A patent/TWI802592B/zh active
- 2018-09-20 AR ARP180102681A patent/AR112901A1/es unknown
-
2020
- 2020-02-18 PH PH12020500353A patent/PH12020500353A1/en unknown
- 2020-02-26 IL IL272933A patent/IL272933A/en unknown
- 2020-03-16 CO CONC2020/0003070A patent/CO2020003070A2/es unknown
- 2020-03-20 CL CL2020000735A patent/CL2020000735A1/es unknown
-
2022
- 2022-12-28 JP JP2022211549A patent/JP2023036901A/ja active Pending
-
2023
- 2023-11-27 US US18/520,348 patent/US20240099980A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1123460T1 (el) | Ενωσεις και μεθοδοι για τη θεραπεια μιας επιληπτικης διαταραχης | |
CY1120398T1 (el) | Ανθρωποποιημενα αντισωματα που αναγνωριζουν αλφα-συνουκλεϊνη | |
EA201991484A1 (ru) | Лекарственные формы энзалутамида | |
CY1118839T1 (el) | Επικαλυμμενη φαρμακευτικη συνθεση που περιεχει ρεγοραφενιμπη | |
UA118453C2 (uk) | Спосіб лікування пухлин у пацієнта | |
MX2018014175A (es) | Conjugados de anticuerpo-fármaco anti-cmet y métodos para su uso. | |
NZ719368A (en) | Combination therapy of antibodies against human csf-1r and uses thereof | |
EA201400565A1 (ru) | Молекулы антител, имеющие специфичность в отношении ох40 человека | |
EA201790305A1 (ru) | КОМБИНИРОВАННАЯ ТЕРАПИЯ БОЛЕЗНИ АЛЬЦГЕЙМЕРА С ИСПОЛЬЗОВАНИЕМ КОМБИНАЦИИ МОНОКЛОНАЛЬНЫХ АНТИТЕЛ К N3pGlu АБЕТА И ИНГИБИТОРА BACE | |
TN2014000513A1 (en) | Dual receptor antagonistic antigen-binding proteins and uses thereof | |
JP2015530399A5 (ru) | ||
EA201791537A1 (ru) | Фармацевтическая композиция на основе наночастиц доцетаксела-альбумина, способ ее получения и ее применение | |
UA118354C2 (uk) | Антитіло до рецептора колонієстимулювального фактора (кфс-1r) | |
EA201300131A1 (ru) | Комбинированная фармацевтическая композиция и методы лечения заболеваний или состояний, связанных с респираторными заболеваниями или состояниями | |
BR112015031417A8 (pt) | forma de dosagem farmacêutica, composição farmacêutica, métodos para tratamento de um paciente com necessidade de cisteamina e para preparo de uma forma de dosagem | |
EA201491281A1 (ru) | КОМПОЗИЦИЯ В ФОРМЕ СУХОГО ПОРОШКА, СОДЕРЖАЩАЯ КОРТИКОСТЕРОИД И β-АДРЕНЕРГИЧЕСКОЕ ЛЕКАРСТВЕННОЕ СРЕДСТВО, ДЛЯ ВВЕДЕНИЯ ИНГАЛЯЦИЕЙ | |
EA201591133A1 (ru) | СОСТАВЫ В ВИДЕ РАСТВОРА СКОНСТРУИРОВАННЫХ АНТИТЕЛ К IL-23p19 | |
EA201691385A1 (ru) | Комбинированная терапия рака | |
EA201691918A1 (ru) | Фармацевтические составы ингибитора киназ семейства raf, способы их получения и способы их применения | |
EA202090014A1 (ru) | Гетероароматические соединения в качестве ингибиторов ванина | |
EA201301264A1 (ru) | Способ получения неорганического материала в виде частиц | |
EA201591513A1 (ru) | Терапевтическое применение антител к vegfr1 (варианты) | |
EA202090640A1 (ru) | Получение твердых лекарственных форм, содержащих антитела, путем наслаивания раствора/суспензии | |
MX2020003031A (es) | Metodo para preparar una forma de dosificacion solida que comprende anticuerpos por granulacion humeda, extrusion y esferonizacion. | |
EA201691299A1 (ru) | Применение лахинимода для замедления прогрессирования болезни хантингтона |